Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be announcing earnings results this Thursday after market hours. Here’s what investors should know.
Amphastar Pharmaceuticals missed analysts’ revenue expectations last quarter, reporting revenues of $183.1 million, down 1.8% year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ revenue estimates and a significant miss of analysts’ EPS estimates.
Is Amphastar Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Amphastar Pharmaceuticals’s revenue to grow 1.5% year on year, improving from its flat revenue in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amphastar Pharmaceuticals has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Amphastar Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 55.5%, beating analysts’ expectations by 13.7%, and Supernus Pharmaceuticals reported revenues up 38.6%, topping estimates by 7.7%. Eli Lilly traded up 13.2% following the results.
Read our full analysis of Eli Lilly’s results here and Supernus Pharmaceuticals’s results here.
There has been positive sentiment among investors in the pharmaceuticals segment, with share prices up 6.5% on average over the last month. Amphastar Pharmaceuticals is up 13.7% during the same time and is heading into earnings with an average analyst price target of $26.86 (compared to the current share price of $23.39).
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.